Search

You searched for "urethral"

340 results found

Renal masses

2 March 2022 | | URO - Urologic Oncology
Case 1 A 70-year-old female presented under the medical team with malaise, weight loss, and deranged liver function tests (LFTs) and calcium (ALP 350, GGT 650, Serum bilirubin 29, normal aminotransferases, Ca 3.3). An abdominal ultrasound scan (USS) was performed...
JAMA Network screengrab image.

Keep an eye on Viagra™

3 February 2023 | | URO - Andrology
Many of the side-effects and contra-indications of sildenafil and other phosphodiesterase 5 (PDE 5) inhibitors for erectile dysfunction have become well known to doctors and pharmacists over the years. This study from the United States collected case reports of adverse...

Endoscopic management of upper tract urothelial carcinoma

1 January 2014 | | URO - Urologic Oncology
Upper tract urothelial carcinoma (UTUC) is a rare disease accounting for 5-10% of all urothelial carcinomas and has an annual incidence in Western countries of 1-2 per 100,000 [1,2]. It occurs more commonly in the pelvicalyceal system as opposed to...

Challenges in urology during and after the COVID-19 pandemic: a trainee perspective

16 May 2022 | | URO - Covid-19
The COVID-19 pandemic has affected urological practice in many ways and at all levels. Social media has been set alight with the hashtag #NoTrainingTodayNoSurgeonsTomorrow highlighting the undesired consequences of the reduction in training opportunities. The impact has been considered by...

What is the role of evidence-based medicine in urology?

1 March 2016 | | URO - Basic Science Research
The concept of ‘evidence-based medicine’ (EBM) was first developed in the early 1990s and was described as “the conscientious, explicit and judicious use of the current best evidence in making decisions about the care of individual patients” by the recently...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

1 January 2016 | | URO - Urologic Oncology, URO - Technology
The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

Training to be a urologist: how risky is it?

1 May 2018 | | URO - Andrology, URO - Basic Science Research, URO - Endourology & Stones, URO - Infection, URO - Neurourology, URO - Paediatric Urology, URO - Functional / Reconstructive Urology, URO - Trauma & Emergency, URO - Urologic Oncology, URO - Uroradiology, URO - Technology
The NHS and urology face challenging times in trying to provide quality patient care efficiently and economically. Urology trainees are experiencing conflicting pressures with a new contract, a challenging on-call system and changing training requirements in an overstretched, centralised service...

An overview of changes to urology training

1 January 2017 | | URO - Core Urology
Paediatric urology training A review of paediatric emergency services in the UK involving general surgery, urology and paediatric surgery was initiated due to the problems encountered by the lack of suitable experience outside large paediatric surgical units to deliver emergency...

An update on lower pole stone management for 2015

1 March 2015 | | URO - Endourology & Stones
Introduction Urolithiasis is an increasing healthcare problem, with an estimated lifetime prevalence of up to 15% [1]. The number of interventions undertaken for stone disease has increased dramatically over recent years, particularly with respect to ureteroscopy and percutaneous nephrolithotomy (PCNL)...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

7 January 2021 | | URO - Urologic Oncology
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

The role of PET-CT imaging in prostate cancer

4 October 2021 | | URO - Urologic Oncology
Prostate cancer (PCa) is the second most common cancer in the UK, with 43,000 cases in 2017-18 [1,2]. Accurate primary staging and the detection of suspected recurrence following treatment is vital for directing management and predicting prognosis. This has conventionally...